Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

203.77
+0.42000.21%
Post-market: 203.770.00000.00%18:35 EDT
Volume:1.38M
Turnover:279.16M
Market Cap:43.68B
PE:-22.84
High:206.36
Open:204.98
Low:197.81
Close:203.35
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:1.07
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.76
PE(LYR):-34.25

Loading ...

Revolution Medicines Faces 'Uphill Battle' in Potential Patent Claim Against Erasca, RBC Says

MT Newswires Live
·
Jun 26

Movement Alert|Revolution Medicines Rises 5.91% in Regular Trading, Rasolute 305 Phase 3 Trial Dosing Initiated and UBS Highlights 40% Revenue Upside

Market Focus
·
Jun 25

Bank of America Securities Sticks to Its Buy Rating for Revolution Medicines (RVMD)

TIPRANKS
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST), Revolution Medicines (RVMD) and Bolt Biotherapeutics (BOLT)

TIPRANKS
·
Jun 25

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 25

Revolution Medicines to Present Phase 1/2 Zoldonrasib-chemo Data in First-line KRAS G12D Metastatic Pancreatic Cancer at ESMO GI 2026

Reuters
·
Jun 25

Revolution Medicines begins treating patients in RASolute 305 trial

TIPRANKS
·
Jun 24

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 23

Revolution Medicines starts Phase 3 RASolute 305 trial of zoldonrasib plus chemotherapy in first-line metastatic RAS G12D pancreatic cancer

Reuters
·
Jun 23

Revolution Medicines Begins Treating Patients in Rasolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination With Chemotherapy as a First Line Treatment for Patients With Ras G12d Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Jun 23

Revolution Medicines' PDAC Revenue Could Rise Up to 40% on Positive Doublet Data, UBS Says

MT Newswires Live
·
Jun 22

Revolution Medicines R&D chief Steve Kelsey to step down as senior adviser July 1

Reuters
·
Jun 22

Revolution Medicines shareholders ratify PwC as auditor for fiscal 2026

Reuters
·
Jun 22

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.d.

THOMSON REUTERS
·
Jun 22

MEDIA-Cancer drugmaker Revolution Medicines says sale not a priority - FT

Reuters
·
Jun 21

Revolution Medicines COO Margaret Horn disposes of 93,575 common shares worth $14.99 million

Reuters
·
Jun 18

Revolution Medicines COO Margaret Horn disposes of 10,000 common shares worth $1.48 million

Reuters
·
Jun 16

Revolution Medicines Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Jun 11

Movement Alert|Revolution Medicines Falls 5.21% in Regular Trading, Trading at $142.305

Market Focus
·
Jun 10

BUZZ-Tango Therapeutics rises premarket after upsized $600 mln equity raise

Reuters
·
Jun 10